Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074

NCT01303744 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: CHF 5074 1x
DRUG: CHF 5074 2x
DRUG: CHF 5074 3x
DRUG: Placebo

Sponsor

CERESPIR